Entrepreneurship and innovation enable Weill Cornell Medicine to bring discoveries to patients faster.

Weill Cornell Medicine investigators enjoy a robust pipeline of dedicated programs capable of taking early discoveries made in academic labs to U.S. Food and Drug Administration-approved testing in clinical trials. Other new initiatives are designed to foster a culture of entrepreneurship and to build the next generation of leaders in life sciences industries and new ventures. 


The Entrepreneurs

Fostering a culture of innovation, Weill Cornell Medicine is making it faster and easier for researchers to move their discoveries from bench to bedside.

Symposium Fosters Entrepreneurial Spirit at Weill Cornell Medicine

The goal of the Dean’s Inaugural Symposium on Opportunities for Entrepreneurship and Academic Drug Development was to highlight resources for investigators to turn their findings into treatments.

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

The Tri-Institutional Therapeutics Discovery Institute, a venture between New York City institutions, creates an accelerated path to treat disease.

BioVenture eLab Opens New Space, Representing Weill Cornell Medicine’s Increased Commitment to Entrepreneurial Ecosystem

Weill Cornell Medicine’s BioVenture eLab, a hub of the institution’s entrepreneurial activity celebrated a milestone on Jan. 23, 2018: the official launch of its new name and space.
Views on Innovation
Dr. Augustine M.K. Choi, the Stephen and Suzanne Weiss Dean
We have recently implemented many initiatives to help our faculty translate their research findings into innovative treatments and therapies for our patients.
Dr. Katherine Hajjar, Associate Dean for Faculty Development
Support from the Daedalus Fund for Innovation is essential, because the usual funding agencies do not support this kind of high-risk applied research.
Dr. William Povino, CEO of Bridge Medicines
Tri-Institutional Therapeutics Discovery Institute and Bridge Medicines put the skill of a pharmaceutical company on the campuses of three great institutions.
Larry Schlossman, Managing Director of BioPharma Alliances and Research Collaborations
We have a fully integrated entrepreneurship ecosystem here. And we really work as a team to help faculty decide what is the best path forward for their project.